Healius Hits All-Time Stock Low After Profit Warning -- Market Talk

Dow Jones

May 13

0138 GMT - Healius's share price drops 22% to an all-time low of A$0.38 after the Australian healthcare company warned on profits. Healius now expects underlying Ebitda of A$259 million-A$264 million in FY 2026. That's well below RBC's A$277 million forecast ahead of today's update. Analyst Craig Wong-Pan says the update implies Healius's pathology volumes deteriorated from 1.2% growth in 1H to a 2.8% decline in the four months through April, while pathology revenue growth fell to 0.7% in 2H so far, from 3.5% in 1H. "We believe Healius has lost share in the 2H period given Medicare pathology volume and benefits paid growth for the three months to March were 1.9% and 1.6% respectively," RBC says. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

May 12, 2026 21:38 ET (01:38 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2635227962"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635227962\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635227962?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635227962","market":"nz","top_or_hot":-1,"title":"Healius Hits All-Time Stock Low After Profit Warning -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0138 GMT - Healius's share price drops 22% to an all-time low of A$0.38 after the Australian healthcare company warned on profits. Healius now expects underlying Ebitda of A$259 million-A$264 million in FY 2026. That's well below RBC's A$277 million forecast ahead of today's update. Analyst Craig Wong-Pan says the update implies Healius's pathology volumes deteriorated from 1.2% growth in 1H to a 2.8% decline in the four months through April, while pathology revenue growth fell to 0.7% in 2H so far, from 3.5% in 1H. \"We believe Healius has lost share in the 2H period given Medicare pathology volume and benefits paid growth for the three months to March were 1.9% and 1.6% respectively,\" RBC says. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 12, 2026 21:38 ET (01:38 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Healius Hits All-Time Stock Low After Profit Warning -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealius Hits All-Time Stock Low After Profit Warning -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-13 09:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0138 GMT - Healius's share price drops 22% to an all-time low of A$0.38 after the Australian healthcare company warned on profits. Healius now expects underlying Ebitda of A$259 million-A$264 million in FY 2026. That's well below RBC's A$277 million forecast ahead of today's update. Analyst Craig Wong-Pan says the update implies Healius's pathology volumes deteriorated from 1.2% growth in 1H to a 2.8% decline in the four months through April, while pathology revenue growth fell to 0.7% in 2H so far, from 3.5% in 1H. \"We believe Healius has lost share in the 2H period given Medicare pathology volume and benefits paid growth for the three months to March were 1.9% and 1.6% respectively,\" RBC says. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 12, 2026 21:38 ET (01:38 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7501","symbol_name":"新冠治疗股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635227962","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635227962","pubTimestamp":1778636280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0138 GMT - Healius's share price drops 22% to an all-time low of A$0.38 after the Australian healthcare company warned on profits. Healius now expects underlying Ebitda of A$259 million-A$264 million in FY 2026. That's well below RBC's A$277 million forecast ahead of today's update. Analyst Craig Wong-Pan says the update implies Healius's pathology volumes deteriorated from 1.2% growth in 1H to a 2.8% decline in the four months through April, while pathology revenue growth fell to 0.7% in 2H so far, from 3.5% in 1H. \"We believe Healius has lost share in the 2H period given Medicare pathology volume and benefits paid growth for the three months to March were 1.9% and 1.6% respectively,\" RBC says. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7501":"新冠治疗股","BK7124":"保健护理服务","BK7509":"中概股","HLS.AU":"HEALIUS LTD"},"translate_title":"Healius在盈利预警后股价创历史新低——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HLS.AU":0.9},"content_text":"0138 GMT - Healius's share price drops 22% to an all-time low of A$0.38 after the Australian healthcare company warned on profits. Healius now expects underlying Ebitda of A$259 million-A$264 million in FY 2026. That's well below RBC's A$277 million forecast ahead of today's update. Analyst Craig Wong-Pan says the update implies Healius's pathology volumes deteriorated from 1.2% growth in 1H to a 2.8% decline in the four months through April, while pathology revenue growth fell to 0.7% in 2H so far, from 3.5% in 1H. \"We believe Healius has lost share in the 2H period given Medicare pathology volume and benefits paid growth for the three months to March were 1.9% and 1.6% respectively,\" RBC says. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 21:38 ET (01:38 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}